pierre-emmanuel noly

Dr. pierre-emmanuel noly

Montreal Heart Institute/Université de Montréal
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
ILIenglam Lei
Ienglam Lei
WHWei Huang
Wei Huang
pierre-emmanuel nolypierre-emmanuel noly
pierre-emmanuel noly
SNSuyash Naik
Suyash Naik
MGMiriyam Ghali
Miriyam Ghali
PTPaul C. Tang
Paul C. Tang
Preservation quality of donor hearts is a key determinant of transplant success. Preservation duration beyond 4 hours is associated with primary graft dysfunction (PGD). Given transport time constraints, geographical limitations exist for donor-recipient matching, leading to donor heart underutilization. Here, we showed that metabolic reprogramming through up-regulation of the enzyme immune response gene 1 (IRG1) and its product itaconate improved heart function after prolonged preservation. Irg1 transcript induction was achieved by adding the histone deacetylase (HDAC) inhibitor valproic acid (VPA) to a histidine-tryptophan-ketoglutarate solution used for donor heart preservation. VPA increased acetylated H3K27 occupancy at the IRG1 enhancer and IRG1 transcript expression in human donor hearts. IRG1 converts aconitate to itaconate, which has both anti-inflammatory and antioxidant properties. Accordingly, our studies showed that Irg1 transcript up-regulation by VPA treatment increased nuclear translocation of nuclear factor erythroid 2–related factor 2 (Nrf2) in mice, which was accompanied by increased antioxidant protein expression [hemeoxygenase 1 (HO1) and superoxide dismutase 1 (SOD1)]. Deletion of Irg1 in mice (Irg1 −/− ) negated the antioxidant and cardioprotective effects of VPA. Consistent with itaconate’s ability to inhibit succinate dehydrogenase, VPA treatment of human hearts increased itaconate availability and reduced succinate accumulation during preservation. VPA similarly increased IRG1 expression in pig donor hearts and improved its function in an ex vivo cardiac perfusion system both at the clinical 4-hour preservation threshold and at 10 hours. These results suggest that augmentation of cardioprotective immune-metabolomic pathways may be a promising therapeutic strategy for improving donor heart function in transplantation.

1 February 2020 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
pierre-emmanuel nolypierre-emmanuel noly
pierre-emmanuel noly
FPFrancis D. Pagani
Francis D. Pagani
NNNicolas Noiseux
Nicolas Noiseux
JSJohn M. Stulak
John M. Stulak
ZKZain Khalpey
Zain Khalpey
SMSimon Maltais
Simon Maltais

16 March 2021 in Membranes
Verified
Journal Article
Open access
PDF file
JBJuan Pablo Ricarte Bratti
Juan Pablo Ricarte Bratti
YCYiorgos Alexandros Cavayas
Yiorgos Alexandros Cavayas
pierre-emmanuel nolypierre-emmanuel noly
pierre-emmanuel noly
KSKarim Serri
Karim Serri
YLYoan Lamarche
Yoan Lamarche
Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is used to sustain circulatory and respiratory support in patients with severe cardiogenic shock or refractory cardiac arrest. Although VA-ECMO allows adequate perfusion of end-organs, it may have detrimental effects on myocardial recovery. Hemodynamic consequences on the left ventricle, such as the increase of afterload, end-diastolic pressure and volume, can lead to left ventricular (LV) distention, increase of myocardial oxygen consumption and delayed LV function recovery. LV distention occurs in almost 50% of patients supported with VA-ECMO and is associated with an increase in morbidity and mortality. Thus, recognizing, preventing and treating LV distention is key in the management of these patients. In this review, we aim to discuss the pathophysiology of LV distention and to describe the strategies to unload the LV in patients supported with VA-ECMO.

1 October 2015 in Archives of Cardiovascular Diseases
Verified
Journal Article
Closed access
JGJulien Guihaire
Julien Guihaire
pierre-emmanuel nolypierre-emmanuel noly
pierre-emmanuel noly
SSSonja Schrepfer
Sonja Schrepfer
OMOlaf Mercier
Olaf Mercier

1 February 2020 in Canadian Journal of Cardiology
Verified
Journal Article
Open access
pierre-emmanuel nolypierre-emmanuel noly
pierre-emmanuel noly
WAWallid Ben Ali
Wallid Ben Ali
YLYoan Lamarche
Yoan Lamarche
MCMichel Carrier
Michel Carrier
The aim of this review is to describe the current use, indications, and outcomes of the Syncardia temporary total artificial heart (TAH) (Syncardia Systems, Tucson, AZ, USA), the only TAH currently approved as a bridge-to-transplant strategy in Canada, the United States, and Europe. With more than 1700 implantations worldwide, the Syncardia temporary TAH is the most commonly used pump. Globally, it represents 2% of the long-term mechanical circulatory support devices implanted, with a recent decrease in its use. The main candidates for TAH are heart transplant candidates suffering from acute or decompensated chronic irreversible biventricular failure at high risk of imminent death and for whom a suitable donor is not available. Most patients receiving a TAH are acutely ill, characterized by an INTERMACS profile of 1 or 2, and 20% are under extracorporeal membrane oxygenation. The TAH provides efficient circulatory support and allows the end-organ to recover from the initial hypoperfusion injury. More than 60% of patients implanted with a Syncardia TAH will later undergo transplantation, with a 1-year survival rate of 70% after transplantation, compared with a 1-year survival rate of ∼ 42% in nontransplant patients. Bleeding, infection, stroke, and acute kidney injury are the most common complications in this critically ill population. The new miniaturization of the console (Freedom Portable Driver) facilitates the recovery of TAH recipients by allowing ambulation, aggressive physiotherapy, and, eventually, hospital discharge. This last aspect is one of the main benefits of TAH compared with other biventricular assist devices. In conclusion, the Syncardia temporary TAH is a reasonable bridge-to-transplant option for selected patients with either biventricular failure or special anatomic conditions.

6 March 2025 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
JGJ. Guzman-Bofarull
J. Guzman-Bofarull
EREduard Ródenas-Alesina
Eduard Ródenas-Alesina
YMY. Moayedi
Y. Moayedi
LTL. Truby
L. Truby
MRM. Rivas-Lasarte
M. Rivas-Lasarte
MFMarta Farrero-Torres
Marta Farrero-Torres